3-28-04

Express Mail No.: EV452774832US

# HE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No : 1866

Application No.: 10/699,110

Group Art Unit: 1614

Filed: October 30, 2003

Examiner: To Be Assigned

For: METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE

Attorney Docket No.: 9516-083-999

INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR

DEGENERATION

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A82 to A86 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application. Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: March 25, 2005

| March 25, 2005 | March 25, 2005 | March 25, 2003 | March 25, 2005 |

JONES DAY 222 East 41st Street

New York, New York 10017-6702

(212) 326-3939

Enclosures

ŝ



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO. 9516-083-999 10/699,110
APPLICANT Zeldis

GROUP

1614

### U.S. PATENT DOCUMENTS

FILING DATE

October 30, 2003

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/ZF/	A82	5,770,589	6/23/98	Billson et al.			
/ZF/	A83	5,605,914	2/25/97	Muller			
	-						
	L						

#### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
					YES	NO
						₩
			1	l		
	DOCUMENT NUMBER	DOCUMENT NUMBER DATE				YES

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/ZF/	A84	Bressler, 1999, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degen with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1," Archives of Ophthalmol. 117(0):1329-1345	
/ZF/	A85	Hunt, 2002, Rostaporfin (Miravant Medical Technologies) IDrugs 5(2):180-186	
/ZF/	A86	Ohno-Matsui et al., 2001, "Novel mechanism for age-related macular degeneration: an equilibrium shift between th angiogenesis factors FEGF and PEDF," J. Cell. Physiol. 189(3):323-333	

	EXAMINER	/Zohreh Fay/ (07/12/2010)	DATE CONSIDERED
1			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.